Drugs / Vamikibart
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06771271 | Jul 2019 → Nov 2023 | diabetic macular edema, macular retinal edema | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT02842541 | Sep 2016 → Oct 2017 | diabetic macular edema | Eleven Biotherapeutics | Withdrawn | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05151731 | Dec 2021 → Nov 2024 | diabetic macular edema | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT05151744 | Dec 2021 → Apr 2024 | diabetic macular edema | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT05642325 | Mar 2023 → May 2025 | macular retinal edema | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT05642312 | Jan 2023 → Dec 2024 | macular retinal edema | Hoffmann-La Roche | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-10-17 | Roche Global Development | Roche presents new phase III pivotal data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss roche.com ↗ |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vamikibart | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05642325 ↗ |
| Known as | EBI-031 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02842541 ↗ |
| Known as | RG-6179 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5315020 ↗ |
| Known as | RO7200220 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06771271 ↗ |
| Action | Inhibit | “Interleukin-6 (IL-6) Inhibitor” NCT02842541 ↗ |
| Modality | Monoclonal antibody | — CHEMBL5315020 ↗ |
| Route | Intravitreal | “given as an intravitreal injection” NCT02842541 ↗ |
| Target | IL6 | “Interleukin-6 (IL-6) Inhibitor” NCT02842541 ↗ |